215 related articles for article (PubMed ID: 24349289)
1. Reverse engineering the neuroblastoma regulatory network uncovers MAX as one of the master regulators of tumor progression.
Albanus RD; Juliani Siqueira Dalmolin R; Alves Castro MA; Augusto de Bittencourt Pasquali M; de Miranda Ramos V; Pens Gelain D; Fonseca Moreira JC
PLoS One; 2013; 8(12):e82457. PubMed ID: 24349289
[TBL] [Abstract][Full Text] [Related]
2. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
[TBL] [Abstract][Full Text] [Related]
3. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.
Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G
Biochim Biophys Acta Gene Regul Mech; 2018 Mar; 1861(3):235-245. PubMed ID: 29408445
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions.
Peverali FA; Orioli D; Tonon L; Ciana P; Bunone G; Negri M; Della-Valle G
Oncogene; 1996 Jan; 12(2):457-62. PubMed ID: 8570225
[TBL] [Abstract][Full Text] [Related]
5. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
6. Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation.
Raschella G; Romeo A; Negroni A; Pucci S; Dominici C; Castello MA; Bevilacqua P; Felsani A; Calabretta B
Cancer Res; 1994 Apr; 54(8):2251-5. PubMed ID: 8174135
[TBL] [Abstract][Full Text] [Related]
7. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
8. The Mlx network: evidence for a parallel Max-like transcriptional network that regulates energy metabolism.
Billin AN; Ayer DE
Curr Top Microbiol Immunol; 2006; 302():255-78. PubMed ID: 16620032
[TBL] [Abstract][Full Text] [Related]
9. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
10. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.
Boboila S; Lopez G; Yu J; Banerjee D; Kadenhe-Chiweshe A; Connolly EP; Kandel JJ; Rajbhandari P; Silva JM; Califano A; Yamashiro DJ
Oncogene; 2018 Oct; 37(40):5451-5465. PubMed ID: 29880876
[TBL] [Abstract][Full Text] [Related]
11. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
12. The mycN/max protein complex in neuroblastoma. Short review.
Wenzel A; Schwab M
Eur J Cancer; 1995; 31A(4):516-9. PubMed ID: 7576956
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic over-expression of multidrug-resistance-related genes is correlated to MYCN and max mRNA accumulation during tumour progression in the IGR-N-91 human neuroblastoma model.
Cappellen D; Bénard J
Int J Cancer; 1997 Feb; 70(4):430-6. PubMed ID: 9033651
[TBL] [Abstract][Full Text] [Related]
14. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin.
Gangoda L; Keerthikumar S; Fonseka P; Edgington LE; Ang CS; Ozcitti C; Bogyo M; Parker BS; Mathivanan S
Oncotarget; 2015 May; 6(13):11175-90. PubMed ID: 25883214
[TBL] [Abstract][Full Text] [Related]
16. Functional and in silico assessment of MAX variants of unknown significance.
Comino-Méndez I; Leandro-García LJ; Montoya G; Inglada-Pérez L; de Cubas AA; Currás-Freixes M; Tysoe C; Izatt L; Letón R; Gómez-Graña Á; Mancikova V; Apellániz-Ruiz M; Mannelli M; Schiavi F; Favier J; Gimenez-Roqueplo AP; Timmers HJ; Roncador G; Garcia JF; Rodríguez-Antona C; Robledo M; Cascón A
J Mol Med (Berl); 2015 Nov; 93(11):1247-55. PubMed ID: 26070438
[TBL] [Abstract][Full Text] [Related]
17. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
[TBL] [Abstract][Full Text] [Related]
18. A dominant-negative mutant of Max that inhibits sequence-specific DNA binding by Myc proteins.
Billaud M; Isselbacher KJ; Bernards R
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2739-43. PubMed ID: 8464883
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Analysis Revealed the Potential Gene Regulatory Processes of ATRA-Triggered Neuroblastoma Differentiation and Identified a Novel RA Response Sequence in the
Guo L; Lin W; Zhang Y; Wang J
Biomed Res Int; 2020; 2020():6734048. PubMed ID: 32149119
[TBL] [Abstract][Full Text] [Related]
20. Structural aspects of interactions within the Myc/Max/Mad network.
Nair SK; Burley SK
Curr Top Microbiol Immunol; 2006; 302():123-43. PubMed ID: 16620027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
